More Focus Needed on Prescribing Disparities for INSTI HIV Treatment
A Pharmacist’s Perspective on the Evidence for Lurbinectedin
Phase 2 Study Finds Tildrakizumab Effective for PsA Manifestations
FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF
Children, Adolescents Considered Obese May Have Greater Risk of NAFLD